Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
Apr 3, 2026
about 1 month ago
Redmile Group's substantial sell-off of Zymeworks shares, totaling $70.10 million, highlights the biotech's challenges amidst fluctuating valuations and a volatile market. Is this a sign of a shift in investor confidence?